Previous close | 65.88 |
Open | 70.00 |
Bid | 47.49 x 200 |
Ask | 82.54 x 200 |
Day's range | 64.05 - 70.00 |
52-week range | 38.91 - 70.81 |
Volume | |
Avg. volume | 151,787 |
Market cap | 1.368B |
Beta (5Y monthly) | 0.81 |
PE ratio (TTM) | 76.71 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
ANI Pharmaceuticals (ANIP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.